{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:59:42Z","timestamp":1790233182964,"version":"4.1.0"},"reference-count":27,"publisher":"American Association for Cancer Research (AACR)","issue":"14","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood and adolescence. Despite advances in therapy, patients with a histologic variant of rhabdomyosarcoma known as alveolar rhabdomyosarcoma (ARMS) have a 5-year survival of &amp;lt;30%. ARMS is characterized by a chromosomal translocation generating the PAX3-FKHR fusion gene. However, ectopic expression of PAX3-FKHR often induces inhibition of cell proliferation, or cell death, when expressed in nonmuscle cells. This prompted us to explore the effect of expressing PAX3-FKHR in more relevant cells, specifically primary human skeletal muscle cells because these cells can be converted to a tumorigenic state that mimics rhabdomyosarcoma. PAX3-FKHR expression promoted both fetal and postnatal primary human skeletal muscle cell precursors to bypass the senescence growth arrest checkpoint. This bypass was accompanied by epigenetic DNA methylation of the p16INK4A promoter and correspondingly a loss of expression of this tumor suppressor. Knockdown of p16INK4A cooperated with PAX3-FKHR to drive proliferation past senescence, whereas reintroduction of wild-type p16INK4A in post-senescent cells caused growth arrest. Thus, PAX3-FKHR acts in concert with loss of p16INK4A to promote inappropriate proliferation of skeletal muscle cells. This association between PAX3-FKHR expression and p16INK4A loss was seen in human ARMS tumor tissue, as both human rhabdomyosarcoma cell lines and tissue microarrays showed a trend toward down-regulation of p16INK4A protein in alveolar subsets. We surmise that the generation of the PAX3-FKHR fusion protein may require loss of p16INK4A to promote malignant proliferation of skeletal muscle cells as an early step in ARMS tumorigenesis. [Cancer Res 2007;67(14):6691\u20139]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-3210","type":"journal-article","created":{"date-parts":[[2007,7,17]],"date-time":"2007-07-17T23:07:57Z","timestamp":1184713677000},"page":"6691-6699","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["The <i>PAX3-FKHR<\/i> Fusion Gene of Rhabdomyosarcoma Cooperates with Loss of p16INK4A to Promote Bypass of Cellular Senescence"],"prefix":"10.1158","volume":"67","author":[{"given":"Corinne M.","family":"Linardic","sequence":"first","affiliation":[{"name":"1Pediatrics, Departments of"},{"name":"2Pharmacology and Cancer Biology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarasija","family":"Naini","sequence":"additional","affiliation":[{"name":"1Pediatrics, Departments of"},{"name":"2Pharmacology and Cancer Biology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"James E.","family":"Herndon","sequence":"additional","affiliation":[{"name":"3Cancer Statistical Center, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chimen","family":"Kesserwan","sequence":"additional","affiliation":[{"name":"5Center for Childhood Cancer, Columbus Children's Research Institute and Children's Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Qualman","sequence":"additional","affiliation":[{"name":"5Center for Childhood Cancer, Columbus Children's Research Institute and Children's Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Counter","sequence":"additional","affiliation":[{"name":"2Pharmacology and Cancer Biology,"},{"name":"4Radiation Oncology, Duke University Medical Center, Durham, North Carolina and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,7,17]]},"reference":[{"key":"2022061623333345900_B1","doi-asserted-by":"crossref","unstructured":"Meyer WH, Spunt SL. Soft tissue sarcomas of childhood. Cancer Treat Rev\u20082004; 30: 269\u201380.","DOI":"10.1016\/j.ctrv.2003.11.001"},{"key":"2022061623333345900_B2","doi-asserted-by":"crossref","unstructured":"Merlino G, Helman LJ. Rhabdomyosarcoma\u2014working out the pathways. Oncogene\u20081999; 18: 5340\u20138.","DOI":"10.1038\/sj.onc.1203038"},{"key":"2022061623333345900_B3","doi-asserted-by":"crossref","unstructured":"Galili N, Davis RJ, Fredericks WJ, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet\u20081993; 5: 230\u20135.","DOI":"10.1038\/ng1193-230"},{"key":"2022061623333345900_B4","unstructured":"Shapiro DN, Sublett JE, Li B, Downing JR, Naeve CW. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res\u20081993; 53: 5108\u201312."},{"key":"2022061623333345900_B5","doi-asserted-by":"crossref","unstructured":"Xia SJ, Pressey JG, Barr FG. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther\u20082002; 1: 97\u2013104.","DOI":"10.4161\/cbt.51"},{"key":"2022061623333345900_B6","doi-asserted-by":"crossref","unstructured":"Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. J Clin Oncol\u20082002; 20: 2672\u20139.","DOI":"10.1200\/JCO.2002.03.137"},{"key":"2022061623333345900_B7","doi-asserted-by":"crossref","unstructured":"van den Broeke LT, Pendleton CD, Mackall C, Helman LJ, Berzofsky JA. Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors. Cancer Res\u20082006; 66: 1818\u201323.","DOI":"10.1158\/0008-5472.CAN-05-2549"},{"key":"2022061623333345900_B8","doi-asserted-by":"crossref","unstructured":"Khan J, Bittner ML, Saal LH, et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci U S A\u20081999; 96: 13264\u20139.","DOI":"10.1073\/pnas.96.23.13264"},{"key":"2022061623333345900_B9","doi-asserted-by":"crossref","unstructured":"Xia SJ, Barr FG. Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein. Oncogene\u20082004; 23: 6864\u201371.","DOI":"10.1038\/sj.onc.1207850"},{"key":"2022061623333345900_B10","doi-asserted-by":"crossref","unstructured":"Bringold F, Serrano M. Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol\u20082000; 35: 317\u201329.","DOI":"10.1016\/S0531-5565(00)00083-8"},{"key":"2022061623333345900_B11","doi-asserted-by":"crossref","unstructured":"Linardic CM, Downie DL, Qualman SJ, Bentley RC, Counter CM. Genetic modeling of human rhabdomyosarcoma. Cancer Res\u20082005; 65: 4490\u20135.","DOI":"10.1158\/0008-5472.CAN-04-3194"},{"key":"2022061623333345900_B12","doi-asserted-by":"crossref","unstructured":"Dickson MA, Hahn WC, Ino Y, et al. Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol\u20082000; 20: 1436\u201347.","DOI":"10.1128\/MCB.20.4.1436-1447.2000"},{"key":"2022061623333345900_B13","doi-asserted-by":"crossref","unstructured":"Bader D, Masaki T, Fischman DA. Immunochemical analysis of myosin heavy chain during avian myogenesis in vivo and in vitro. J Cell Biol\u20081982; 95: 763\u201370.","DOI":"10.1083\/jcb.95.3.763"},{"key":"2022061623333345900_B14","doi-asserted-by":"crossref","unstructured":"Morotti RA, Nicol KK, Parham DM, et al. An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience. Am J Surg Pathol\u20082006; 30: 962\u20138.","DOI":"10.1097\/00000478-200608000-00005"},{"key":"2022061623333345900_B15","doi-asserted-by":"crossref","unstructured":"Qualman SJ, Coffin CM, Newton WA, et al. Intergroup Rhabdomyosarcoma Study: update for pathologists. Pediatr Dev Pathol\u20081998; 1: 550\u201361.","DOI":"10.1007\/s100249900076"},{"key":"2022061623333345900_B16","doi-asserted-by":"crossref","unstructured":"Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene\u20082004; 23: 2919\u201333.","DOI":"10.1038\/sj.onc.1207518"},{"key":"2022061623333345900_B17","doi-asserted-by":"crossref","unstructured":"Brenner AJ, Stampfer MR, Aldaz CM. Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. Oncogene\u20081998; 17: 199\u2013205.","DOI":"10.1038\/sj.onc.1201919"},{"key":"2022061623333345900_B18","doi-asserted-by":"crossref","unstructured":"Sharpless NE, DePinho RA. Telomeres, stem cells, senescence, and cancer. J Clin Invest\u20082004; 113: 160\u20138.","DOI":"10.1172\/JCI20761"},{"key":"2022061623333345900_B19","doi-asserted-by":"crossref","unstructured":"Rocco JW, Sidransky D. p16(MTS-1\/CDKN2\/INK4a) in cancer progression. Exp Cell Res\u20082001; 264: 42\u201355.","DOI":"10.1006\/excr.2000.5149"},{"key":"2022061623333345900_B20","doi-asserted-by":"crossref","unstructured":"Guney I, Sedivy JM. Cellular senescence, epigenetic switches, and c-Myc. Cell Cycle\u20082006; 5: 2319\u201323.","DOI":"10.4161\/cc.5.20.3348"},{"key":"2022061623333345900_B21","doi-asserted-by":"crossref","unstructured":"Wei W, Herbig U, Wei S, Dutriaux A, Sedivy JM. Loss of retinoblastoma but not p16 function allows bypass of replicative senescence in human fibroblasts. EMBO Rep\u20082003; 4: 1061\u20136.","DOI":"10.1038\/sj.embor.7400001"},{"key":"2022061623333345900_B22","doi-asserted-by":"crossref","unstructured":"Urashima M, Teoh G, Akiyama M, Yuza Y, Anderson KC, Maekawa K. Restoration of p16INK4A protein induces myogenic differentiation in RD rhabdomyosarcoma cells. Br J Cancer\u20081999; 79: 1032\u20136.","DOI":"10.1038\/sj.bjc.6690165"},{"key":"2022061623333345900_B23","doi-asserted-by":"crossref","unstructured":"Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma\u2014a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol\u20082003; 21: 78\u201384.","DOI":"10.1200\/JCO.2003.06.129"},{"key":"2022061623333345900_B24","doi-asserted-by":"crossref","unstructured":"Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature\u20082005; 436: 117\u201322.","DOI":"10.1038\/nature03664"},{"key":"2022061623333345900_B25","doi-asserted-by":"crossref","unstructured":"Maelandsmo GM, Berner JM, Florenes VA, et al. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas\u2014relationship to amplification and mRNA levels of CDK4 and CCND1. Br J Cancer\u20081995; 72: 393\u20138.","DOI":"10.1038\/bjc.1995.344"},{"key":"2022061623333345900_B26","doi-asserted-by":"crossref","unstructured":"Iolascon A, Faienza MF, Coppola B, et al. Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. Genes Chromosomes Cancer\u20081996; 15: 217\u201322.","DOI":"10.1002\/(SICI)1098-2264(199604)15:4<217::AID-GCC3>3.0.CO;2-4"},{"key":"2022061623333345900_B27","doi-asserted-by":"crossref","unstructured":"Obana K, Yang HW, Piao HY, et al. Aberrations of p16INK4A, p14ARF, and p15INK4B genes in pediatric solid tumors. Int J Oncol\u20082003; 23: 1151\u20137.","DOI":"10.3892\/ijo.23.4.1151"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/14\/6691\/2570702\/6691.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/14\/6691\/2570702\/6691.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T03:40:45Z","timestamp":1655437245000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/14\/6691\/533242\/The-PAX3-FKHR-Fusion-Gene-of-Rhabdomyosarcoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,15]]},"references-count":27,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2007,7,17]]},"published-print":{"date-parts":[[2007,7,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-3210","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,15]]}}}